Secondary Stock OfferingsBy The Online Investor Staff, updated Thu., Feb. 27, 4:02 PM
|This Slide: #18 of 25|
Slide #18. PDS Biotechnology Corporation — Secondary Offering
PDS Biotechnology Corporation (NASDAQ:PDSB)
Date of Pricing:
Price Per Share:
Secondary Offering Details:
PDS Biotechnology Corporation ("PDS Biotechnology") (Nasdaq: PDSB), a clinical-stage immuno-oncology company developing multiple therapies based on PDS Biotechnology's proprietary Versamune T-cell activating technology, today announced the pricing of an underwritten public offering consisting of 9,230,770 shares of common stock at a price to the public of $1.30 per share. The gross proceeds to PDS Biotechnology from this offering are expected to be approximately $12,000,000, before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on Friday, February 14, 2020, subject to customary closing conditions.
PDS Biotechnology is a clinical stage immuno-oncology company with a pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. All of Co.'s products are based on the proprietary Versamune® platform technology, which activates and directs the human immune system against cancer cells.
Open the PDSB Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 86% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite